Macintyre Iain M, Dhaun Neeraj, Goddard Jane, Webb David J
Clinical Pharmacology Unit, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK.
Drugs Today (Barc). 2008 Dec;44(12):875-85. doi: 10.1358/dot.2008.44.12.1310761.
Ambrisentan is the second selective endothelin-A receptor antagonist to be licensed in Europe, and the first in the United States, for the management of pulmonary arterial hypertension (PAH). It has been shown to be clinically effective in improving exercise tolerance and functional class. Furthermore, ambrisentan is well tolerated and associated with low rates of liver toxicity and minimal interactions with other medicines commonly used to treat PAH. Overall, current data support a role for ambrisentan in the management of PAH. However, the results of longer-term follow-up studies are still required to fully assess efficacy and safety.
安立生坦是欧洲获批的第二种选择性内皮素-A受体拮抗剂，也是美国获批的第一种用于治疗肺动脉高压（PAH）的此类药物。已证明其在改善运动耐量和功能分级方面具有临床疗效。此外，安立生坦耐受性良好，肝毒性发生率低，与常用于治疗PAH的其他药物相互作用极小。总体而言，现有数据支持安立生坦在PAH治疗中的作用。然而，仍需要长期随访研究的结果来全面评估其疗效和安全性。
